Higher screening rates along with treatment advances have reduced breast cancer deaths by 42% in recent decades. Still, it remains the second deadliest cancer among women in the United States, with over 40,000 expected to die of the disease last year. And for the almost 4 million women living with breast cancer, the physical and mental… Continue reading Clinical Trials Are Testing Ways to Prevent Breast Cancer
Tag: Cancer Genetics and Genomics
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
Background B-Raf proto-oncogene, serine/threonine kinase (BRAF)V600E-mutant microsatellite stable (MSS) colorectal cancer (CRC) constitutes a distinct CRC subgroup, traditionally perceived as minimally responsive to standard therapies. Recent clinical attempts, such as BRAF inhibitors (BRAFi) monotherapy and combining BRAFi with other inhibitors, have yielded unsatisfactory efficacy. This study aims to identify a novel therapeutic strategy for this… Continue reading HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer
A new approach for detecting HPV DNA in cervical swabs: comparison of nucleic acid extraction with direct PCR
Almost all cases of cervical cancer are associated with persistent high-risk HPV infection. WHO prioritizes primary HPV testing for cervical cancer screening. Cervical cancer screening programs require the abi… Continue reading on BioMed Central
Experts Forecast Cancer Research and Treatment Advances in 2025
Every new year brings excitement and anticipation for what might happen over the next 12 months. So, what’s in store for 2025 that could change the way we diagnose and treat cancer? What first-in-class therapeutics could offer new life-saving options to patients? What scientific discovery will have everyone talking? In 2024, we saw the approval… Continue reading Experts Forecast Cancer Research and Treatment Advances in 2025
Error in Co–First Author Designation
The Review titled “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review,” published online on July 25, 2024, and in the September 2024 issue was corrected to add co–first author designation for the second author in the byline, Jeffrey W. Shevach, MD. This article has been corrected online.
Researchers resolve uncertainty in BRCA2 testing, improving cancer risk assessment and patient care
Findings from a multi-institutional, international study have significantly advanced the understanding of genetic alterations in the BRCA2 gene, a key player in hereditary cancer risk.
Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression
Background The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of TP53 pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of MDM2 amplification in UC remain unclear. Methods… Continue reading Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression
A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India
Abstract Background Lip and oral cavity cancer is leading cause of cancer mortality among Indian men. This study evaluated diagnostic accuracy of mobile health (mHealth) enabled screening for early detection of oral premalignant lesions or oral cancer (OPML/OC). It also described epidemiology of tobacco and other substance use and associated oral lesions in rural northern… Continue reading A prospective study on diagnostic accuracy of technology‐enabled early detection of oral cancer and epidemiology of tobacco and other substances use in rural India
Feasibility of a cancer screening program using multicancer early detection testing and whole‐body magnetic resonance imaging in a high‐risk population
Abstract Background The authors assessed the feasibility, acceptability, and impact on cancer worry of a cancer screening program using multicancer early detection (MCED) tests and whole-body magnetic resonance imaging (WBM) in individuals at high cancer risk because of family history or germline variants in cancer-susceptibility genes. Methods This prospective trial enrolled participants aged 50 years… Continue reading Feasibility of a cancer screening program using multicancer early detection testing and whole‐body magnetic resonance imaging in a high‐risk population
Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study
Zanubrutinib in combination with R-CHOP in double-expressor lymphoma patients. Abstract Background Double-expressor lymphoma (DEL) has a poorer prognosis than other subtypes of diffuse large B-cell lymphoma (DLBCL). This study is a multicenter, prospective, single-arm, phase 2 clinical study initiated by investigators to evaluate the efficacy and safety of combined zanubrutinib with R-CHOP, which includes rituximab,… Continue reading Zanubrutinib plus R‐CHOP for the treatment of newly diagnosed double‐expressor lymphoma: A phase 2 clinical study